)
)
Cadrenal Therapeutics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Cadrenal Therapeutics, Inc.
Access all reports
Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on the development of tecarfarin, an advanced oral anticoagulant. Tecarfarin is designed to prevent heart attacks, strokes, and deaths caused by blood clots, particularly in patients with rare cardiovascular conditions that require long-term anticoagulation therapy. These conditions include end-stage kidney disease (ESKD), atrial fibrillation, and complications related to left ventricular assist devices (LVADs). The company aims to address the limitations of existing anticoagulants like warfarin, offering a more stable and reliable treatment option through an alternative metabolic pathway. The company is headquartered in Ponte Vedra, Florida, and its shares are listed on the NASDAQ.
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
CVKD
Country
🇺🇸 United States